Hypoxia is prevalent in human tumours and contributes to microenvironments that shape
cancer evolution and adversely affect therapeutic outcomes. Historically, two different …

Cancer is a multi-step disease caused by the accumulation of genetic mutations and/or
epigenetic changes, and is the biggest challenge around the world. Cytokines, including …

Cancer immunotherapy by immune checkpoint blockade has proven its great potential by
saving the lives of a proportion of late stage patients with immunogenic tumor types …

Cancer therapy has developed around the concept of killing, or stop** the growth of, the
cancer cells. Molecularly targeted therapy is the modern expression of this paradigm …

The chemokine CXCL12 promotes glioblastoma (GBM) recurrence after radiotherapy (RT)
by facilitating vasculogenesis. Here we report outcomes of the dose-escalation part of …

Glioblastoma (GBM) is the most aggressive, malignant primary brain tumor in adults. GBM is
notoriously resistant to immunotherapy mainly due to its unique immune microenvironment …

High-grade gliomas are rapidly progressing tumors of the central nervous system (CNS) with
a very poor prognosis despite extensive resection combined with radiation and/or …

Chemokines are crucial autocrine and paracrine players in tumor development. In particular,
CXCL12, through its receptors CXCR4 and CXCR7, affects tumor progression by controlling …

Glioblastoma is the most common form of primary brain tumour in adults. For more than a
decade, conventional treatment has produced a relatively modest improvement in the …

The tumor microenvironment has an important influence on cancer biological and clinical
behavior and radiation treatment (RT) response. However, RT also influences the tumor …